Medplus Health Services Ltd

NSE: MEDPLUS · BSE: 543427 · Healthcare · 22 announcements

Share price: ₹654.90
Market cap: ₹7,868 Cr
Revenue (annual): ₹6,892 Cr
Net profit (annual): ₹219.7 Cr
P/E (TTM): 37.4×Sector 57.8×
Promoter holding: 40.19%-0.03% QoQ
FII holding: 14.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Legal & Regulatory 7 Adverse Business Impact 6 Other Announcement 1 Board Meeting Outcome 1 Acquisition 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

6 announcements with these filters

25 Sep 2026 19:09 IST BSE

Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.

Value: ₹0.01 Cr
From: Drugs Control Administration, Haveri Circle, Karnataka

Read the filing ↗

16 Sep 2026 17:20 IST BSE

Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.

Value: ₹0.02 Cr
Execution: 7 days

Read the filing ↗

12 Sep 2026 13:56 IST BSE

Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.

Value: ₹0.10 Cr
Execution: 5 to 15 days

Read the filing ↗

10 Sep 2026 17:07 IST BSE

Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced a five-day drug license suspension at its Kapikad store due to regulatory violations. The impact is Rs 0.03 Crore.

Value: ₹0.03 Cr
suspension period: 5.0 days

Read the filing ↗

5 Sep 2026 17:21 IST BSE

Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health's subsidiary faces temporary drug license suspensions at two store locations in Bangalore and Pune, resulting in an estimated financial impact of Rs 0.15 Crore.

Value: ₹0.15 Cr

Read the filing ↗

4 Sep 2026 17:53 IST BSE

Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus's subsidiary faces a 7-day drug license suspension at a Maharashtra store, with an estimated financial impact of Rs 0.0175 Crore.

Value: ₹0.02 Cr
Execution: 7 days

Read the filing ↗